Request Demo

Last update 16 Sep 2026

Gabapentin

Last update 16 Sep 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryGabapentin is a small molecule drug developed by Pfizer that functions as a CACNA2D2 and Cav2.2 blocker. The drug has been approved for the treatment of various conditions, including anxiety, cough, diabetic neuropathies, epilepsy, fibromyalgia, restless legs syndrome, and seizures. Gabapentin's mechanism of action involves blocking the influx of calcium ions into neurons, thereby reducing their excitability and relieving symptoms such as pain and convulsions. Since its initial approval in 1993, Gabapentin has become a widely prescribed medication for the treatment of these conditions. However, it is important to note that Gabapentin may cause certain side effects, such as drowsiness, dizziness, and difficulty with coordination. Therefore, its use must be closely monitored by healthcare providers, and patients should follow the prescribed dosage and usage guidelines.

Drug Type

Small molecule drug

Synonyms

1-(Aminomethyl)cyclohexaneacetic acid, Gabapentin (JAN/USP/INN), CI-945

+ [17]

Target

CACNA2D1 x CACNA2D2

Action

blockers

Mechanism

CACNA2D1 blockers(Voltage-gated calcium channel alpha2/delta subunit 1 blockers), CACNA2D2 blockers(Voltage-gated calcium channel alpha2/delta subunit 2 blockers)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesEndocrinology and Metabolic Disease+ [3]

Active Indication

NeuralgiaPeripheral neuralgiaNeuralgia, Postherpetic+ [9]

Inactive Indication

Amyotrophic Lateral SclerosisCarpal Tunnel SyndromeDyspepsia+ [8]

Originator Organization

Pfizer Inc.

Active Organization

Viatris Pharma GmbHViatris Specialty LLC

Pfizer Inc.

+ [6]

Inactive Organization

Gebr. Gödecke Beteiligungs- und Verwaltungsgesellschaft mbH

Assertio Therapeutics, Inc.

Viatris, Inc.

+ [2]

License Organization

Fuji Pharma Co., Ltd.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Lotus Pharmaceutical Co., Ltd.

+ [7]

Drug Highest PhaseApproved

First Approval Date

United States (30 Dec 1993),

Anxiety DisordersCoughDiabetic Neuropathies+ [5]

RegulationOrphan Drug (United States)

Structure/Sequence

Molecular FormulaC9H17NO2

InChIKeyUGJMXCAKCUNAIE-UHFFFAOYSA-N

CAS Registry60142-96-3

747

Clinical Trials associated with Gabapentin

CTIS2026-526884-39-00

/ Not yet recruitingPhase 3IIT

Effect of GABAergic treatments on cortical plasticity and motor learning capacity in the subacute phase after stroke: a single-case experimental study (GABAPLAST)

Start Date01 Oct 2026

Sponsor / Collaborator

Le Centre Hospitalier Universitaire de Toulouse

JPRN-jRCT1031260476

/ RecruitingPhase 2

Efficacy and Safety of Gabapentin for Cough in Patients with Cancer: A Multicenter, Single-Arm, Prospective, Exploratory Study

Start Date11 Sep 2026

Sponsor / Collaborator-

ChiCTR2600130783

/ SuspendedNot ApplicableIIT

Local Incisional Glucocorticoid Injection Combined With Perioperative Gabapentin for the Prevention of Chronic Postsurgical Pain After Thoracoscopic Pulmonary Resection: A Multicenter Randomized Controlled Trial

Start Date01 Sep 2026

Sponsor / Collaborator-

100 Clinical Results associated with Gabapentin

100 Translational Medicine associated with Gabapentin

100 Patents (Medical) associated with Gabapentin

9,718

Literatures (Medical) associated with Gabapentin

01 Jan 2027·JOURNAL OF ETHNOPHARMACOLOGY

Antihyperalgesic and antiallodynic effects of Salvia rosmarinus Spenn. extracts and some of their bioactive metabolites in a murine fibromyalgia pain model

Article

Author: González-Trujano, María Eva ; Déciga-Campos, Myrna ; Ovalle-Magallanes, Berenice ; Siles-Guevara, Janet

ETHNOPHARMACOLOGICAL RELEVANCE:

Fibromyalgia (FM) is a chronic nociplastic pain syndrome characterized by widespread pain, allodynia, and hyperalgesia. Current pharmacological treatments have limited efficacy and may cause adverse effects. Salvia rosmarinus (rosemary) is a medicinal plant traditionally used to relieve different types of pain and other conditions, as reported in preclinical and clinical studies. However, its potential efficacy in relieving FM pain has not been fully characterized.

AIM OF THE STUDY:

To evaluate the antiallodynic and antihyperalgesic effects of extracts with different polarities obtained from the aerial parts of S. rosmarinus, as well as some of its bioactive metabolites, in male and female Wistar rats in the reserpine-induced FM model.

MATERIAL AND METHODS:

Essential oil and hexane extracts were prepared as non-polar extracts, whereas ethanolic and aqueous extracts were used as polar extracts of S. rosmarinus aerial parts at 10-300 mg/kg, i.p., and evaluated for antihyperalgesic and tactile and thermal antiallodynia activities in reserpine-induced fibromyalgia in rats; gabapentin (30 mg/kg, i.p.) was used as the reference drug. Representative bioactive metabolites of each extract were also assessed.

RESULTS:

All extracts produced significant antiallodynic and antihyperalgesic effects, with the ethanolic extract showing the greatest activity. The metabolites hesperidin, caffeic acid, and limonene were partially responsible for these effects.

CONCLUSIONS:

These results support the potential of S. rosmarinus and its metabolites as therapeutic alternatives for relieving nociplastic pain associated with FM.

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK

Article

Author: Kanumilli, Naresh ; Evans, Jerome ; Cattin, Juliette ; Debackere, Nele ; Osumili, Beatrice ; Buckingham, Mike ; Hunt, Barnaby ; Webb, Joanne ; Nowakowski, Piotr

INTRODUCTION:

Tirzepatide is a treatment for type 2 diabetes associated with improvements in glycemic control and weight loss, and a low risk of hypoglycemia when not used in combination with insulin or insulin secretagogues. A cost to target analysis of tirzepatide 5, 10 and 15 mg versus subcutaneous semaglutide 1 mg in the UK setting was performed, calculating the annual pharmacy cost per patient treated to six composite endpoints combining glycemic control (glycated hemoglobin [HbA1c] ≤ 6.5% [48 mmol/mol] and <7.0% [53 mmol/mol]) with weight loss (≥5%, ≥10%, ≥15%) and avoidance of hypoglycemia. The costing analysis was based on the tirzepatide costs appraised by NICE as part of TA924.

METHODS:

The proportions of patients achieving composite treatment targets with tirzepatide and semaglutide (both in combination with metformin) were taken from a post-hoc analysis of the SURPASS-2 clinical trial (N = 1,845). Costs per patient treated to target were calculated by dividing the annual treatment costs associated with each intervention by the proportion of patients achieving the treatment target with each intervention.

RESULTS:

Tirzepatide 5, 10 and 15 mg were associated with a lower pharmacy cost per patient achieving treatment target than semaglutide 1 mg for the majority of endpoints evaluated. Differences became greater at more strict treatment targets. For example, the cost per patient achieving HbA1c ≤6.5%, weight loss ≥15%, and no hypoglycemia was GBP 5,650, GBP 8,665 and GBP 9,462 lower with tirzepatide 5, 10 and 15 mg, respectively, compared with semaglutide 1 mg over a 1-year time horizon. The only endpoint where semaglutide 1 mg was associated with a lower cost per patient achieving target was HbA1c <7.0%, weight loss ≥5%, and no hypoglycemia.

CONCLUSIONS:

Compared to semaglutide, tirzepatide was associated with a lower annual pharmacy cost per patient with diabetes achieving treatment target in the UK for the majority of endpoints, with greater differences at more strict treatment targets.

31 Dec 2026·COPD-Journal of Chronic Obstructive Pulmonary Disease

Prescribing Patterns of Gabapentinoids in Patients with Chronic Obstructive Pulmonary Disorder

Article

Author: Bullock, Reece ; Dimit, Alexandra ; Patel, Manysha ; Englehart, Anika ; Soric, Mate Michael ; King, Olivia ; Bole, Kelly ; Mara, Nita ; Vergara, Mollie ; Moqbl, Amgad ; Skory, Brandon

In 2019, the U.S. Food and Drug Administration (FDA) issued a warning regarding the risk of serious respiratory depression in patients using gabapentin or pregabalin who have respiratory risk factors, including those with chronic obstructive pulmonary disorder (COPD). With the overall prescribing of gabapentinoids continuing to grow, there is the potential for inappropriate prescribing in this patient population. Data from the National Ambulatory Medical Care Survey (NAMCS) from 2013 to 2018, with the exception of 2017, was used to assess prevalence and predictors of gabapentinoid prescribing in patients with COPD. The data consists of 1,131 unweighted visits, representing approximately 53.6 million ambulatory care visits nationally. Of these visits, 146 patients (10.8%) with a COPD diagnosis were also prescribed a gabapentinoid, which represents more than a million office visits annually when weighted. Patients with an increased risk of receiving gabapentinoids were those with concomitant diabetes mellitus, concurrent opioid use, and those currently using tobacco. Due to increased risk of serious respiratory depression caused by gabapentinoids, prescribers should take caution when prescribing to individuals with COPD and other respiratory risk factors. Based on the reviewed prescribing patterns, more education is needed to inform providers about the risks associated with concomitant COPD and gabapentinoid use.

News (Medical) associated with Gabapentin

15 Sep 2026

·www.prnewswire.com

Braeburn Announces Publication of Postmarketing Safety Analysis Evaluating BRIXADI® in The Journal of Substance Use & Addiction Treatment

PLYMOUTH MEETING, Pa., Sept. 15, 2026 /PRNewswire/ -- Braeburn today announced the publication of a study in The Journal of Substance Use & Addiction Treatment (JSAT) examining adverse events (AEs) reported to the FDA Adverse Event Reporting System (FAERS) during the first 18 months following the U.S. commercial launch of Weekly and Monthly BRIXADI® (buprenorphine) extended-release injection for subcutaneous use (CIII). The full publication, "Adverse events reported to FDA Adverse Event Reporting System for long-acting injectable buprenorphine during the first 18 months postlaunch," is available online at JSAT today. "Clinicians have had to rely primarily on clinical trials to understand the safety profile of long-acting injectable buprenorphine formulations," said Brian Dawson, MD, FASAM, Chief Medical Officer at Ideal Option. "Postmarketing reporting to the FAERS helps give us a fuller picture by providing safety insights across the broader U.S. patient population." "These real-world data help support informed decision-making for healthcare professionals managing this disease," said Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer at Braeburn. About the Analysis A retrospective review of the FAERS was conducted examining case reports submitted during the 6-, 12-, and 18-month periods following the U.S. commercial launch of each FDA-approved long-acting injectable buprenorphine product. About BRIXADI® BRIXADI is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. BRIXADI should be used as part of a complete treatment plan that includes counseling and psychosocial support. IMPORTANT SAFETY INFORMATION WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; BRIXADI RISK EVALUATION AND MITIGATION STRATEGY Serious harm or death could result if administered intravenously. BRIXADI forms a liquid crystalline gel upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life-threatening pulmonary emboli, if administered intravenously. Because of the risk of serious harm or death that could result from intravenous self-administration, BRIXADI is only available through a restricted program called the BRIXADI REMS. Healthcare settings and pharmacies that order and dispense BRIXADI must be certified in this program and comply with the REMS requirements. BRIXADI (buprenorphine) extended-release injection (weekly, 50 mg/mL buprenorphine) and BRIXADI (monthly, 356 mg/mL buprenorphine) are different formulations. Doses of BRIXADI (weekly) cannot be combined to yield an equivalent monthly dose. CONTRAINDICATIONS BRIXADI is contraindicated in patients with hypersensitivity (e.g., anaphylactic shock) to buprenorphine or any other ingredients in the solution for injection. WARNINGS AND PRECAUTIONS Addiction, Abuse, and Misuse: BRIXADI contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Buprenorphine is sought by people with opioid use disorder and is subject to criminal diversion. Monitor all patients for progression of opioid dependence and addictive behaviors. Life-Threatening Respiratory and Central Nervous System (CNS) Depression: Buprenorphine has been associated with life-threatening respiratory depression and death. Use BRIXADI with caution in patients with compromised respiratory function. Due to its extended-release characteristics, if BRIXADI is discontinued as a result of compromised respiratory function, monitor patients for ongoing buprenorphine effects for approximately 1 month for BRIXADI (weekly) and for approximately 4 months for BRIXADI (monthly). Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose. Patient Access to an Opioid Overdose Reversal Agent for the Emergency Treatment of Opioid Overdose: Inform patients and caregivers about opioid overdose reversal agents (e.g., naloxone, nalmefene) and discuss the importance of having access to an opioid overdose reversal agent. Because patients being treated for opioid use disorder have the potential for relapse, putting them at risk for opioid overdose, strongly consider prescribing or recommending an opioid overdose reversal agent for the emergency treatment of an opioid overdose, both when initiating and renewing treatment with BRIXADI. If an opioid overdose reversal agent is prescribed, educate patients and caregivers on how to treat with such an agent, and emphasize the importance of calling 911 or getting emergency medical help, even if an agent is administered. Concomitant Use of Benzodiazepines or other CNS Depressants: Concomitant use of buprenorphine and benzodiazepines or other CNS depressants (e.g., alcohol, non-benzodiazepine sedative/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids [gabapentin or pregabalin], and other opioids) increases the risk of adverse reactions including overdose, respiratory depression, and death. Ensure that other healthcare providers prescribing benzodiazepines or other CNS depressants are aware of the patient's buprenorphine treatment and coordinate care to minimize the risk associated with concomitant use. Inform patients and caregivers that potentially fatal additive effects may occur if BRIXADI is used with benzodiazepines or other CNS depressants, including alcohol, and not to use these concomitantly unless supervised by a healthcare provider. Neonatal Opioid Withdrawal Syndrome, Pregnancy, and Lactation: Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy. NOWS may be life-threatening if not recognized and treated in the neonate. Healthcare providers should observe newborns for signs of NOWS and manage accordingly. Advise pregnant women receiving opioid addiction treatment with BRIXADI of the risk of neonatal opioid withdrawal syndrome. Warn patients that buprenorphine passes into breast milk. Advise the nursing mother taking buprenorphine to monitor the infant for increased drowsiness and breathing difficulties. Adrenal Insufficiency: If adrenal insufficiency is diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid. Risk of Opioid Withdrawal with Abrupt Discontinuation: Patients who elect to discontinue BRIXADI treatment should be monitored for withdrawal signs and symptoms with consideration given to the product's extended-release characteristics. Risk of Hepatitis, Hepatic Events, and Use in Patients with Impaired Hepatic Function: Liver function tests should be performed on all patients prior to initiation, during treatment, and if a hepatic event is suspected. Because buprenorphine levels cannot be rapidly decreased, patients with pre‐existing moderate to severe hepatic impairment are not candidates for treatment with BRIXADI. Patients who develop moderate to severe hepatic impairment while being treated with BRIXADI should be monitored for signs and symptoms of toxicity or overdose of buprenorphine and may require a dose adjustment. Hypersensitivity Reactions: Cases of bronchospasm, angioneurotic edema, and anaphylactic shock have been reported in patients receiving buprenorphine-containing products. The most common signs and symptoms include rashes, hives, and pruritus. The BRIXADI needle cap is synthetically derived from natural rubber latex which may cause allergic reactions in latex-sensitive individuals. Precipitation of Opioid Withdrawal in Patients Dependent on Full Opioid Agonists: BRIXADI injection may precipitate opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists such as heroin, morphine, or methadone before the effects of the full opioid agonist have subsided. In patients who are new entrants to treatment, to avoid precipitating an opioid withdrawal syndrome, administer a 4 mg test dose of transmucosal buprenorphine when objective signs of mild to moderate withdrawal appear and monitor for precipitated withdrawal before injecting BRIXADI. Risks Associated with Treatment of Emergent Acute Pain: While on BRIXADI, situations may arise where patients need acute pain management, or may require anesthesia. Treat patients receiving BRIXADI with non-opioid analgesic whenever possible. Patients requiring opioid therapy for analgesia may be treated with a high-affinity full opioid analgesic under the supervision of a healthcare provider, with particular attention to respiratory function. Higher doses may be required for analgesic effect. Therefore, a higher potential for toxicity exists with opioid administration. Advise patients of the importance of instructing their family members, in the event of emergency, to inform the treating healthcare provider or emergency room staff that the patient is being treated with BRIXADI. Use in Opioid Naïve Patients: There have been reported deaths of opioid naïve individuals who received a 2 mg dose of buprenorphine as a sublingual tablet. BRIXADI is not appropriate for use in opioid naïve patients. Patients at Risk for Arrhythmia: Thorough QT studies with buprenorphine products have demonstrated QT prolongation ≤ 15 msec. This QTc prolongation effect does not appear to be mediated by hERG channels. Based on these two findings, buprenorphine is unlikely to be pro-arrhythmic when used alone in patients without risk factors. The risk of combining buprenorphine with other QT-prolonging agents is not known. Impairment of Ability to Drive and Operate Machinery: BRIXADI may impair the mental or physical abilities required for the performance of potentially dangerous tasks such as driving a car or operating machinery. Caution patients about driving or operating hazardous machinery until they are reasonably certain that BRIXADI does not adversely affect their ability to engage in such activities. Orthostatic Hypotension: Buprenorphine may produce orthostatic hypotension in ambulatory patients. Elevation of Cerebrospinal Fluid Pressure: Buprenorphine may elevate cerebrospinal fluid pressure and should be used with caution in patients with head injury, intracranial lesions, and other circumstances when cerebrospinal pressure may be increased. Elevation of Intracholedochal Pressure: Buprenorphine has been shown to increase intracholedochal pressure, as do other opioids, and thus should be administered with caution to patients with dysfunction of the biliary tract. Effects in Acute Abdominal Conditions: Buprenorphine may obscure the diagnosis or clinical course of patients with acute abdominal conditions. Unintentional Pediatric Exposure: Buprenorphine can cause severe, possibly fatal, respiratory depression in children who are accidentally exposed to it. ADVERSE REACTIONS Adverse reactions commonly associated with BRIXADI administration (in ≥5% of patients) were injection site pain, headache, constipation, nausea, injection site erythema, injection site pruritus, insomnia, and urinary tract infection. DRUG INTERACTIONS CYP3A4 Inhibitors and Inducers: Monitor patients starting or ending CYP3A4 inhibitors or inducers for potential over or under dosing. Serotonergic Drugs: If concomitant use is warranted, monitor for serotonin syndrome, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. USE IN SPECIFIC POPULATIONS Lactation: Buprenorphine passes into the mother's milk. The development and health benefits of breastfeeding should be considered along with the mother's clinical need for buprenorphine treatment and any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition. Geriatric Patients: Monitor geriatric patients receiving BRIXADI for sedation or respiratory depression. Moderate to Severe Hepatic Impairment: BRIXADI is not recommended for use in patients with pre-existing moderate to severe hepatic impairment. To report SUSPECTED ADVERSE REACTIONS, contact Braeburn at 1-833-274-9234 or FDA at 1-800-FDA-1088 or . Please see the BRIXADI Medication Guide and Full Prescribing Information , including BOXED WARNING, at BRIXADI.com or accompanying this document. About Braeburn Braeburn is dedicated to delivering solutions for people living with the serious consequences of opioid use disorder. At Braeburn, we challenge the status quo and champion transformation of the management of opioid use disorder (OUD) by partnering with the community to create a world where every person with OUD gets the best possible care and opportunity to reach their full potential. Visit braeburnrx.com to learn more. Connect with Braeburn on LinkedIn at linkedin.com/company/braeburn. For additional information, please contact: Sabrina Romano, Senior Manager of Corporate Communications & Advocacy, at [email protected] BRX-1836 August 2026 SOURCE Braeburn 21% more press release views with Request a Demo

22 Jul 2026

·www.einpresswire.com

Virginia Family Chiropractic Expands NeuroMed Neuropathy Program at Manassas Clinic on Dorsey Circle

Non-drug NeuroMed protocol combines neuromuscular stimulation and MLS laser therapy for diabetic and idiopathic neuropathy patients in Prince William County. MANASSAS, VA, UNITED STATES, July 22, 2026 / EINPresswire.com / -- Virginia Family Chiropractic has expanded access to its NeuroMed neuropathy protocol at the Manassas clinic on Dorsey Circle, giving Prince William County residents a non-pharmaceutical pathway for treating diabetic peripheral neuropathy, idiopathic nerve pain, and related conditions including carpal tunnel syndrome and post-herpetic neuralgia. The expansion responds to a widening gap in neurological care outside the immediate Washington, D.C. metro corridor. Peripheral neuropathy affects an estimated 20 million Americans, and roughly half of adults living with diabetes develop some form of nerve damage during their lifetime. Approximately one in four peripheral neuropathy cases is classified as idiopathic, meaning no clear underlying cause is identified — and conventional treatment has historically been limited to prescription medications carrying significant side-effect profiles. At the Manassas location, the NeuroMed protocol combines two distinct technologies. The NeuroMed system delivers targeted neuromuscular stimulation and biofeedback intended to support nerve regeneration in the affected extremities. Sessions are paired with MLS Laser Therapy, an FDA-cleared dual-wavelength laser that alternates continuous and pulsed emissions of infrared light to reduce inflammation and stimulate cellular repair at depths conventional cold lasers do not reach. "When patients arrive here after trying gabapentin or duloxetine without meaningful relief, they're often surprised that a non-drug pathway even exists," said Dr. Ghazaleh Tabrizi, board-certified chiropractor at Virginia Family Chiropractic in Manassas, VA . "Combining neuromuscular stimulation with MLS laser gives us two mechanisms working on the nerve at once — something a single-modality office can't offer." Dr. Tabrizi holds a Doctor of Chiropractic from Cleveland Chiropractic College Los Angeles and is also a certified personal trainer and weight-management specialist — a combination that supports the metabolic and lifestyle counseling that often accompanies diabetic neuropathy treatment. The clinical team at Virginia Family Chiropractic works alongside a Family Nurse Practitioner and a supervising Medical Doctor, an integrated model that permits coordinated evaluation rather than referrals scattered across separate offices. The Manassas clinic, located at 8420 Dorsey Circle across from UVA Health Prince William Medical Center, serves patients throughout Manassas, Manassas Park, Gainesville, Bristow, and Haymarket. The office sits within reach of Interstate 66 and Route 28, which matters in a region where average one-way commute times exceed 33 minutes and where scheduling recurring therapy sessions is a practical concern for working adults and retirees on fixed transportation. Candidates for the program begin with a diagnostic evaluation to determine whether nerve damage is diabetic, chemotherapy-induced, alcohol-related, post-surgical, or idiopathic in origin. Treatment plans typically involve multiple sessions per week over an initial course of care, with progress measured through sensation testing, mobility benchmarks, and patient-reported symptom tracking. The Manassas office accepts Virginia workers' compensation, automobile injury claims, and a range of private health insurance plans; coverage is verified prior to the initial visit. The Manassas office joins three sister clinics in Alexandria, Falls Church, and Woodbridge, each staffed with CBP-certified providers and equipped with matching diagnostic and treatment technology. About Virginia Family Chiropractic Founded in 2008, Virginia Family Chiropractic operates four Northern Virginia clinics offering evidence-based chiropractic care, physical medicine, and rehabilitation services. The practice emphasizes the Chiropractic BioPhysics protocol, non-pharmaceutical pain management, and integrated medical oversight, treating patients of all ages for conditions ranging from acute back pain to chronic neurological disorders. The Manassas office at 8420 Dorsey Circle is open Monday through Friday from 8:00 a.m. to 6:00 p.m. and Saturday from 9:00 a.m. to 1:00 p.m. For appointments, visit https://virginiafamilychiropractic.com/chiropractor-manassas-va or call (703) 367-7878. ### Media Contact Virginia Family Chiropractic Address: 8420 Dorsey Cir STE 101, Manassas, VA 20110 Phone: (703) 367-7878 Website: https://virginiafamilychiropractic.com/chiropractor-manassas-va Dr. Cameron Hatam Virginia Family Chiropractic (Manassas, VA) +1 703-367-7878 N/A Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

07 Jul 2026

·www.prnewswire.com

Invictus Pharmacy and Mullan Pharmaceutical Inc. Announce Strategic Partnership to Expand Patient Access to FDA-Approved Ganirelix Acetate Injection Through Invictus Pharmacy

Partnership Leverages Invictus Pharmacy's Direct-to-Patient Nationwide Licensed Platform to Deliver FDA-Approved Ganirelix Acetate Injection Across All 50 States NEW YORK, July 7, 2026 /PRNewswire/ -- Invictus Pharmacy, a vertically integrated, nationwide licensed pharmacy platform managed by Invictus Ventures Inc., and Mullan Pharmaceutical Inc., a U.S.-based pharmaceutical company committed to expanding access to affordable, FDA-approved medications through high-capacity manufacturing partnerships and distribution, today announced a strategic partnership to expand patient access to Ganirelix Acetate Injection, 250 mcg/0.5 mL, for patients undergoing fertility treatment across the United States. Continue Reading Mullan Pharma Under the terms of the partnership, Mullan will supply Ganirelix Acetate Injection to Invictus Pharmacy, which, as a licensed dispensing pharmacy, will fulfill valid patient prescriptions through its nationally licensed digital and mail-order pharmacy infrastructure. Through this collaboration, Invictus Pharmacy will help connect fertility patients with this time-sensitive IVF medication with greater speed, transparency, and affordability. Improving Access for Patients During One of Medicine's Most Time-Sensitive Treatments Ganirelix Acetate Injection is a synthetic decapeptide GnRH antagonist indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) as part of an assisted reproductive technology (ART) protocol, including in vitro fertilization (IVF). The medication is administered as a once-daily subcutaneous injection during the mid-to-late follicular phase of the IVF cycle and plays a pivotal role in synchronizing follicular development, preventing premature ovulation, and optimizing the timing of egg retrieval. For fertility patients, timely, uninterrupted access to Ganirelix Acetate is not merely a matter of convenience — it is clinically essential. Treatment windows are measured in days, and even brief disruptions in medication supply can compromise an entire IVF cycle. This partnership is designed to eliminate those disruptions by ensuring the FDA-approved Ganirelix Acetate Injection is reliably supplied to Invictus Pharmacy, which dispenses it to patients pursuant to valid prescriptions through its nationwide licensed fulfillment platform. Invictus Pharmacy on Patient Access and Affordability "Fertility treatment demands precision. From the clinic, from the physician, and from the pharmacy," said Meyer Davidoff , Founder and Chief Executive Officer of Invictus Pharmacy. "At Invictus, our mission is to remove unnecessary barriers between patients and the medications they are prescribed by combining nationwide licensed pharmacy fulfillment, transparent pricing, and direct collaboration with manufacturers. This partnership reflects the broader purpose of our platform: to create a faster, more affordable, and more reliable prescription access model for patients during moments when timing and trust matter most." Advancing Access to Affordable FDA-Approved Medicines "Mullan's mission is straightforward: expand access to vital and essential medicines for every patient," said Marineh Malek, PharmD, RPh, Chief Pharmaceutical Affairs & Regulatory Compliance Officer, Mullan Pharmaceutical Inc. "Ganirelix Acetate is one of the most time-critical medications in reproductive medicine, and the patients who need it are among the most vulnerable in our healthcare system. Invictus Pharmacy's nationwide licensure, dispensing and fulfillment infrastructure, and commitment to transparent pricing make them an ideal partner to ensure that no patient faces an unnecessary barrier to obtaining this medication." Partnership Highlights The collaboration between Invictus Pharmacy and Mullan Pharmaceutical Inc. delivers tangible benefits to patients, fertility specialists, and the reproductive medicine ecosystem: Nationwide Home Delivery: Invictus Pharmacy holds pharmacy licensure across all 50 U.S. states and territories, enabling home delivery of Ganirelix Acetate Injection to fertility patients regardless of geographic location — eliminating the need for patients to source time-sensitive injectable medications from local specialty pharmacies. Direct-to-Patient Pricing: Consistent with Invictus Pharmacy's model of partnering directly to bypass traditional pharmacy benefit intermediaries, this partnership will enable transparent, competitive pricing for Ganirelix Acetate Injection, reducing out-of-pocket costs for patients at one of the most financially demanding stages of fertility treatment. Seamless Digital Experience: Patients will manage their Ganirelix Acetate prescriptions through Invictus Pharmacy's proprietary e-commerce platform at InvictusPharmacy.com, featuring prescription tracking, price transparency, and digital health program integration. Storage and Fulfillment Expertise: Invictus Pharmacy's advanced platform and pharmacy fulfillment infrastructure are designed to ensure uninterrupted prescription access, with particular attention to the handling requirements of injectable fertility medications. About Ganirelix Acetate Injection Ganirelix Acetate Injection, 250 mcg/0.5 mL, is an FDA-approved, single-dose, sterile, prefilled syringe intended for subcutaneous administration. As a GnRH antagonist, Ganirelix Acetate competitively blocks GnRH receptors on the pituitary gland, inducing rapid and reversible suppression of LH and FSH secretion. It is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation in connection with an ART program. Ganirelix Acetate Injection is a prescription medicine. Pregnancy must be excluded before initiating treatment. Important safety information applies. Patients should consult their reproductive endocrinologist or fertility specialist to determine if Ganirelix Acetate is appropriate for their treatment protocol. Please refer to the full Prescribing Information. About Invictus Pharmacy Founded in 2017, Invictus Pharmacy is a vertically integrated, nationwide pharmacy platform specializing in direct-to-consumer prescription access. Managed by New York–based Invictus Ventures Inc., the company operates a network of retail locations, a nationally licensed mail-order pharmacy, a proprietary e-commerce platform, and a claims adjudication technology system. Invictus Pharmacy has served more than one million patients and holds pharmacy licensure across all 50 U.S. states and territories, with its mail-order facility located in New Jersey. Invictus partners directly with drug manufacturers to deliver transparent, direct-to-consumer pricing on brand and generic medications, bypassing traditional pharmacy benefit intermediaries to lower costs and expand patient access. About Invictus Ventures Inc. Invictus Ventures Inc. is a privately held New York–based healthcare technology and pharmacy management company focused on expanding transparent, affordable prescription access for patients, employers, payers, and drug manufacturers. The company manages Invictus Pharmacy, a vertically integrated, nationwide licensed pharmacy platform with retail, mail-order, digital pharmacy, telehealth, claims adjudication, and direct-to-patient fulfillment capabilities, and is developing the TAB Drug Cost Manager platform, an AI-enabled prescription cost optimization system designed to help employers, self-funded health plans, individuals, and manufacturers identify lower-cost dispensing pathways, The company is headquartered at 150 East 52nd Street, Suite 16003, New York, NY 10022. About Mullan Pharmaceutical Inc. Mullan Pharmaceutical Inc. is a U.S.-based pharmaceutical company focused on expanding access to affordable, FDA-approved medications through high-capacity manufacturing partnerships, product registration, and global distribution. Founded in 2022 as a subsidiary of Pasaca Capital, Mullan brings deep expertise in distribution, operations, and a strong capital base to its mission of ensuring that patients and healthcare providers can reliably access high-quality medications at affordable costs. Mullan's product portfolio includes Ganirelix Acetate Injection, Labetalol Hydrochloride Injection, Argatroban Injection, Sevoflurane, and a range of oral solid dosage forms including Metformin, Gabapentin, Bupropion XL, and Celecoxib. The company is headquartered at 800 E Colorado Blvd., Suite 888, Pasadena, CA. For more information, visit . Forward-Looking Statements: This press release contains forward-looking statements. Actual results may differ materially from those anticipated. SOURCE Invictus Pharmacy 21% more press release views with Request a Demo

License out/in

100 Deals associated with Gabapentin

External Link

KEGG	Wiki	ATC	Drug Bank
D00332	Gabapentin	N03AX12	DB00996

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Neuralgia	Australia	Micro Labs Pty Ltd.	20 Aug 2026
Peripheral neuralgia	Belgium	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Czechia	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	France	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Germany	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Hungary	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Iceland	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Ireland	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Italy	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Latvia	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Luxembourg	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Netherlands	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Norway	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Poland	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Portugal	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Slovenia	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	Sweden	Viatris Pharma GmbH	27 Oct 2006
Peripheral neuralgia	United Kingdom	Viatris Pharma GmbH	27 Oct 2006
Neuralgia, Postherpetic	United States	Viatris Specialty LLC	02 Mar 2000
Anxiety Disorders	Japan	Pfizer Inc.	30 Dec 1993

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Analgesia	NDA/BLA	Canada	Rubicon Research Ltd.	01 Nov 2025
Dyspepsia	Phase 3	United States	Pfizer Inc.	01 Mar 2010
Refractory chronic cough	Phase 3	Australia	Hunter New England Area Health Service	15 Oct 2008
Hot Flashes	Phase 3	United States	Assertio Therapeutics, Inc.	01 Sep 2008
Vasomotor symptom	Phase 3	United States	Assertio Therapeutics, Inc.	01 Sep 2008
Sleep Initiation and Maintenance Disorders	Phase 3	United States	Viatris, Inc.	01 Oct 2004
Tremor	Phase 3	United States	Pfizer Inc.	01 Mar 2004
Carpal Tunnel Syndrome	Phase 3	Hong Kong	Pfizer Inc.	01 Oct 2003
Amyotrophic Lateral Sclerosis	Phase 3	United States	Pfizer Inc.	31 Dec 1999
Tinnitus	Phase 2	Iran	Islamic Azad University of Mashhad	01 Jan 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04246697 (CTgov)	Phase 4	Analgesia \| Head and Neck Neoplasms	30	Tylenol+Oxycodone+Morphine (Standard of Care A)	yjstgfplls(mgvxbmwcus) = zelggqjkpm xvcxazbvub (yiiysukula, 121.4) View more	-	07 Jul 2026
				Tylenol+Oxycodone+toradol+Morphine+Bupivacaine+Gabapentin (Standard of Care B)	yjstgfplls(mgvxbmwcus) = qylbjmgzwh xvcxazbvub (yiiysukula, 100.0) View more
NCT03220776 (Pubmed \| Transl Psychiatry)	Phase 2	Alcohol Use Disorder	54	N-acetylcysteine (NAC)	nnraxunawn(cuxhiyhtka) = ahtfgfloox cuaixyqrxn (kkrargcvxp, 4.6) View more	Positive	03 Jun 2026
				Placebo	nnraxunawn(cuxhiyhtka) = uhthlupaog cuaixyqrxn (kkrargcvxp, 4.55) View more
NCT05076110 (CTgov)	Phase 4	Pain	86	Oxycodone (Standard of Care Group)	ortoocuruh(vxrnfatuwe) = klnmcjjywl ypqmlxxibi (dwogwpuroo, 0.2) View more	-	03 Jun 2026
				Acetaminophen+Methocarbamol+Ibuprofen+Gabapentin (Non-Opiate Pain Control Group)	ortoocuruh(vxrnfatuwe) = jgxprunpea ypqmlxxibi (dwogwpuroo, 0.2) View more
ATS2026	Not Applicable	Idiopathic Pulmonary Fibrosis	46,749	Guaifenesin	eakqpeeycm(wtbshynvmi): OR = 1.203 (95.0% CI, 1.051 - 1.377) View more	Positive	15 May 2026
				Benzonatate
DDW2026	Not Applicable	Chronic Pain	15,198	Gabapentin	zbsqcuvjwk(suotwhnjfj) = nnehsgtmck bmnfwprktj (yoevnsogby ) View more	Positive	02 May 2026
				Duloxetine	zbsqcuvjwk(suotwhnjfj) = xhplkmgele bmnfwprktj (yoevnsogby ) View more
NCT03574792 (CTgov)	Phase 2	Pain \| Cutaneous Squamous Cell Carcinoma of the Head and Neck	62	Quality-of-Life Assessment+Oxycodone+Methadone+Gabapentin (Arm I (Gabapentin, Methadone, Oxycodone))	gzhmrndhfg(lyzxuewwuo) = ribetnfwvk nwlvnancrj (rogygtucqe, 10) View more	-	16 Apr 2026
				Quality-of-Life Assessment+Oxycodone+Methadone+Venlafaxine+Gabapentin (Arm II (Gabapentin, Methadone, Oxycodone, Venlafaxine))	gzhmrndhfg(lyzxuewwuo) = smbelnowcd nwlvnancrj (rogygtucqe, 17) View more
NCT05658874 (CTgov)	Phase 3	Cystitis, Interstitial \| Blepharospasm \| Chronic pelvic pain syndrome	26	Behavioral health consultation/therapy+heparin+gentamicin+sodium bicarb+Kenalog+Vaginal estrogen+Gabapentin+Oxybutynin+Detrol+Mirabegron+lidocaine+Amitriptyline+Trospium+Methenamine (Multimodal Care Bundle)	rdfmlwfpuc(bqzzevhuct) = gmxsflxicg yyoftonpdv (nsctsohcld, 7.11) View more	-	01 Apr 2026
				Usual Urogynecologic care (Usual Care)	rdfmlwfpuc(bqzzevhuct) = pjmdpqjino yyoftonpdv (nsctsohcld, 7.34) View more
NCT03818932 (CTgov)	Phase 2/3	Analgesia \| Anterior Cruciate Ligament Injuries	90	Acetaminophen+Diazepam+Ketorolac+celecoxib+Gabapentin (Post-Operative Non Opioid Pain Protocol)	fvschctebq(vnxdsvbcef) = sifpfqmvrq rtrqbffinn (thitvmiiyt, enimhlqdxx - etpufqttyd) View more	-	19 Mar 2026
				Hydrocodone-Acetaminophen (Post-Operative Traditional Pain Protocol)	fvschctebq(vnxdsvbcef) = lqpctookmb rtrqbffinn (thitvmiiyt, iqwmleicby - mrkfwdmfuu) View more
NCT04705480 (CTgov)	Phase 4	Pain	109	Pregabalin 50mg (Pregabalin)	sknrxtzwbs(ezjjmiwdpe) = gzkvwiorqk pqsgjrelyu (yyonzaclij, ppvdmhuqti - pfmgmzgkab) View more	-	06 Jan 2026
				Gabapentin 300mg (Gabapentin)	sknrxtzwbs(ezjjmiwdpe) = vpjtvgabgg pqsgjrelyu (yyonzaclij, hxzysqgohl - wvyexamddm) View more
ACR2025	Not Applicable	Fibromyalgia	500	gabapentins + gabapentin	iqqzrqesez(gymwibweuh) = ksrlfphghq ebhvjuktih (ubgthtxyto ) View more	Negative	24 Oct 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis